PetMed Express, Inc. (NASDAQ:PETS) Short Interest Update
by Amy Steele · The Cerbat GemPetMed Express, Inc. (NASDAQ:PETS – Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,698,921 shares, an increase of 68.2% from the November 30th total of 1,604,421 shares. Based on an average daily trading volume, of 12,363,353 shares, the short-interest ratio is presently 0.2 days. Approximately 12.9% of the shares of the stock are short sold. Approximately 12.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 12,363,353 shares, the short-interest ratio is presently 0.2 days.
PetMed Express Trading Down 2.3%
Shares of PetMed Express stock traded down $0.08 during trading hours on Friday, hitting $3.47. 108,088 shares of the company were exchanged, compared to its average volume of 7,696,855. The stock has a market capitalization of $74.15 million, a price-to-earnings ratio of -1.31 and a beta of 0.75. The business has a 50-day moving average of $2.46 and a 200-day moving average of $2.86. PetMed Express has a 1 year low of $1.57 and a 1 year high of $5.58.
PetMed Express (NASDAQ:PETS – Get Free Report) last announced its quarterly earnings data on Friday, December 19th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.45). PetMed Express had a negative net margin of 28.22% and a negative return on equity of 40.26%. The company had revenue of $44.36 million during the quarter. As a group, research analysts anticipate that PetMed Express will post 0.19 earnings per share for the current fiscal year.
Institutional Investors Weigh In On PetMed Express
Several hedge funds have recently made changes to their positions in the business. R Squared Ltd acquired a new position in PetMed Express during the 2nd quarter worth approximately $34,000. Occudo Quantitative Strategies LP acquired a new stake in PetMed Express during the 2nd quarter valued at $51,000. Oxford Asset Management LLP acquired a new stake in PetMed Express during the 2nd quarter valued at $55,000. CIBC Private Wealth Group LLC purchased a new stake in PetMed Express during the 3rd quarter worth $75,000. Finally, Bridgeway Capital Management LLC lifted its holdings in PetMed Express by 96.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company’s stock worth $135,000 after buying an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 73.33% of the company’s stock.
Analyst Ratings Changes
Several analysts have recently issued reports on PETS shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PetMed Express in a research report on Wednesday, October 8th. Zacks Research upgraded PetMed Express from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Wall Street Zen downgraded PetMed Express from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. One research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell” and an average price target of $3.20.
Get Our Latest Research Report on PetMed Express
About PetMed Express
PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.
Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.